MLM Share Price

Open 0.43 Change Price %
High 0.43 1 Day 0.00 0.00
Low 0.43 1 Week 0.00 0.00
Close 0.43 1 Month 0.02 4.88
Volume 965814 1 Year 0.09 26.47
52 Week High 0.64
52 Week Low 0.31
MLM Important Levels
Resistance 2 0.43
Resistance 1 0.43
Pivot 0.43
Support 1 0.43
Support 2 0.43
BIT Italy Most Active Stocks
ISP 2.85 -0.70%
TIT 0.81 -1.22%
PMI 0.36 0.00%
PMI 0.36 0.00%
ENEL 4.91 -0.20%
TITR 0.64 -1.54%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
More..
BIT Italy Top Gainers Stocks
NR 0.43 53.57%
NR 0.43 53.57%
NR 0.43 53.57%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
BRI 0.08 14.29%
BRI 0.08 14.29%
BRI 0.08 14.29%
More..
BIT Italy Top Losers Stocks
ME 0.09 -10.00%
ME 0.09 -10.00%
PRS 0.10 -9.09%
PRS 0.10 -9.09%
PRS 0.10 -9.09%
PRS 0.10 -9.09%
MON 0.21 -8.70%
MON 0.21 -8.70%
MON 0.21 -8.70%
MON 0.21 -8.70%
More..

Molmed (BIT: MLM)

MLM Technical Analysis 3
As on 21st Jul 2017 MLM Share Price closed @ 0.43 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.44 & Sell for SHORT-TERM with Stoploss of 0.43 we also expect STOCK to react on Following IMPORTANT LEVELS.
MLM Target for July
1st Target up-side 0.46
2nd Target up-side 0.48
3rd Target up-side 0.5
1st Target down-side 0.4
2nd Target down-side 0.38
3rd Target down-side 0.36
MLM Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.molmed.com
MLM Address
MLM
Via Olgettina, 58
Milan, MI 20132
Italy
Phone: 39 02 212771
Fax: 39 02 21 27 73 25
MLM Latest News
Progenics Azedra Succeeds in Mid-Stage Trials (PGNX)   Investopedia   - 30th Mar 17
Progenics Pharmaceuticals Announces Positive Topline Results from ...   GlobeNewswire (press release)   - 30th Mar 17
Berlusconi Campaigns for 'No' as His Top Managers Back Renzi   Bloomberg   - 23rd Nov 16
The Mast Cell: New Target in SpA?   MedPage Today   - 12th Nov 16
A Pedicure Will Not Cure Postpartum Depression   American Council on Science and Health   - 04th Nov 16
Molecular Epidemiology of Staphylococcus aureus in the General Population in ...   Journal of Clinical Microbiology   - 24th Oct 16
DiaSorin SpA Completes Acquisition of the Focus Diagnostics' Molecular and ...   PR Newswire (press release)   - 14th May 16
DiaSorin To Acquire Focus Diagnostics' Molecular And Immunoassay Product ...   PR Newswire (press release)   - 30th Mar 16
Discoveries: In western Sonoma County, ferment in the finest cedar chips   Sacramento Bee   - 13th Feb 16
Molecular Medicine SpA : MolMed clinical development update: four studies ...   4-traders (press release)   - 16th May 13
Interactive Technical Analysis Chart Molmed ( MLM BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Molmed
MLM Business Profile
MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of therapies to treat cancer. Its products include TK, a cell therapy product, which is in Phase III clinical trials enabling safe transplant of haematopoietic stem cells from partially compatible haplo-identical donors for the treatment of haematological malignancies. The company’s products also comprise NGR-hTNF, a recombinant biological drug that is in Phase II clinical trials for various types of solid tumours, such as colorectal, hepatocellular carcinoma and mesothelioma, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as is in Phase III clinical trials in mesothelioma patients. It has an agreement with Telethon Foundation for the co-development and clinical-grade manufacture of gene therapies for rare genetic diseases; San Raffaele Foundation for the clinical-grade manufacturing of a cell therapy for Duchenne muscular dystrophy; and GlaxoSmithKline for the development and production for clinical use of a viral vector for ADA, as well as a strategic partnership with Takara Bio, Inc. for TK cell therapy. The company was founded in 1996 and is based in Milan, Italy.